[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 8 days · First seen · Last updated

Medical and pharmaceutical company financial reports

Overview

Recent financial reports from the medical and pharmaceutical sectors show varying growth trajectories.

Più Medical reported a 31% increase in pro-forma consolidated revenues for the first half of 2026, reaching 17.5 million euros. While the company's pro-forma net result rose to 603,000 euros, its consolidated adjusted EBITDA decreased from 2 million to 1.8 million euros, a margin contraction attributed to investments in recent acquisitions and central structure strengthening.

Valbiotis, a French laboratory focused on cardiometabolic health, reported a 130% increase in half-year revenue to €0.8 million. The company noted a cash position of €11.7 million and international expansion through agreements in China and the Middle East. However, Valbiotis has withdrawn its previously communicated financial ambitions for the 2026-2030 period.

Entities

Valbiotis · Euronext Growth Milan

Timeline

  1. [BUSINESS] 2 sources
    Valbiotis reports 130% revenue growth in first half of 2026

    French cardiometabolic health laboratory Valbiotis reported a 130% increase in first-half 2026 revenue to €0.8 million and announced international expansion plans.

  2. [BUSINESS] 2 sources
    Più Medical reports 31% revenue growth in first half of 2026

    Più Medical reported a 31% increase in first-half 2026 revenues to 17.5 million euros, driven by pharmacy growth despite lower consolidated EBITDA margins due to integration investments.

Sources

marketwire.com · pharmacyscanner.it · teleborsa.it · webdisclosure.com